公开(公告)号：US11896663B2

公开(公告)日：2024-02-13

申请号：US17190569

申请日：2021-03-03

Applicant: Janssen Vaccines & Prevention B.V.

Inventor： Johannes Petrus Maria Langedijk ,  Danielle Van Manen ,  Jort Vellinga ,  Frank Wegmann ,  Benoit Christophe Stephan Callendret ,  Anders Krarup ,  Jörn Stitz

IPC: A61K39/21 ,  C07K14/16 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N15/861 ,  A61K39/00

CPC classification number: A61K39/21 ,  C07K14/005 ,  C07K14/162 ,  C12N7/00 ,  C12N15/86 ,  A61K2039/5256 ,  C12N15/861 ,  C12N2710/10343 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16234

Abstract: Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.

公开(公告)号：US20180318350A1

公开(公告)日：2018-11-08

申请号：US15773783

申请日：2016-11-04

Applicant: Emory University ,  St. Jude Children's Hospital, Inc.

Inventor： Rafi AHMED ,  Benjamin YOUNGBLOOD

IPC: A61K35/17 ,  C12N9/10 ,  C12N5/0783 ,  C07K14/705 ,  A61P31/14 ,  A61P35/00 ,  C07K14/005

CPC classification number: A61K35/17 ,  A61P31/14 ,  A61P35/00 ,  C07K14/005 ,  C07K14/70596 ,  C12N5/0636 ,  C12N5/10 ,  C12N9/1007 ,  C12N2740/16033 ,  C12N2740/16111 ,  C12Y201/01037

Abstract: This disclosure relates to the genetic modification of DNMT3A gene in immune cells. In certain embodiments, the modified immune cells may be used in adoptive T cells therapies to enhance immune responses against cancer or chronic infections. In certain embodiments, the disclosure relates to deleting, changing, or inserting nucleotides within the DNMT3A gene in immune cells, e.g., human CD8 T cells, such that the DNMT3A gene product does not function for methylation. In certain embodiments, modification of the DNMT3A gene provides an improvement in antigen-specific T cells functions and/or an enhancement of the longevity of the cells.

公开(公告)号：US20180186839A1

公开(公告)日：2018-07-05

申请号：US15897554

申请日：2018-02-15

Applicant: Beth Israel Deaconess Medical Center

Inventor： Dan H. BAROUCH ,  Joseph Patrick NKOLOLA

IPC: C07K14/005 ,  A61K39/21 ,  A61K39/12 ,  C07K14/16 ,  A61K39/00

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/55505 ,  A61K2039/55561 ,  A61K2039/55566 ,  C07K14/162 ,  C12N2740/16034 ,  C12N2740/16111

Abstract: The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.

公开(公告)号：US09944679B2

公开(公告)日：2018-04-17

申请号：US14806751

申请日：2015-07-23

Applicant: THE CATHOLIC UNIVERSITY OF AMERICA

Inventor： Venigalla B. Rao ,  Wadad Alsalmi

IPC: C07K14/16 ,  C07K14/005 ,  C12N7/00 ,  A61K9/70 ,  A61K39/21 ,  C07K1/22 ,  C07K1/36 ,  A61K39/12 ,  A61K39/00

CPC classification number: C07K14/005 ,  A61K9/7023 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/54 ,  A61K2039/627 ,  C07K1/22 ,  C07K1/36 ,  C07K14/162 ,  C07K2319/00 ,  C07K2319/20 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/40 ,  C07K2319/50 ,  C12N7/00 ,  C12N2740/16022 ,  C12N2740/16043 ,  C12N2740/16051 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16234

Abstract: Provided herein are HIV vaccines that encompasses recombinant trimers that mimic native HIV-1 envelope trimers. Also provided are methods of administering to a subject in need thereof an HIV vaccine provided herein to elicit antibodies against a recombinant trimer in the subject. A recombinant trimer is formed by a recombinant protein comprising a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140, wherein the linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix during purification of the recombinant trimer.

公开(公告)号：US20180066023A1

公开(公告)日：2018-03-08

申请号：US15817761

申请日：2017-11-20

Applicant: The Catholic University of America

Inventor： Venigalla B. RAO ,  Wadad ALSALMI

IPC: C07K14/005 ,  A61K9/70 ,  C12N7/00

CPC classification number: C07K14/005 ,  A61K9/7023 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/54 ,  A61K2039/627 ,  C07K1/22 ,  C07K1/36 ,  C07K14/162 ,  C07K2319/00 ,  C07K2319/20 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/40 ,  C07K2319/50 ,  C12N7/00 ,  C12N2740/16022 ,  C12N2740/16043 ,  C12N2740/16051 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16234

Abstract: An approach of producing recombinant trimers that mimic native HIV-1 envelope trimers is developed. A recombinant protein forming the recombinant trimers encompasses a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140. The linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix. After expressed in a cell, the recombinant protein is secreted into the culture medium and assembles into recombinant trimers therein. The recombinant trimers may be directly purified from the culture medium. Cleaved and uncleaved trimers from different clade viruses are produced.

公开(公告)号：US09580473B2

公开(公告)日：2017-02-28

申请号：US12303985

申请日：2007-06-08

Applicant: Drew Weissman ,  Earl Stoddard

Inventor： Drew Weissman ,  Earl Stoddard

IPC: A61K38/10 ,  C07K7/08 ,  C07K16/28 ,  C07K14/16 ,  C07K14/005 ,  C07K14/47 ,  A61K39/395 ,  A61K38/00

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K38/10 ,  A61K39/395 ,  C07K7/08 ,  C07K14/162 ,  C07K14/47 ,  C07K16/28 ,  C07K2299/00 ,  C12N2740/16111 ,  C12N2740/16122

Abstract: This invention relates to methods compositions and devices for inhibiting infection of a subject's host cell by HIV. Specifically, the invention relates to methods and compositions capable of inhibiting the binding and subsequent infection by HIV of a host cell through the inhibition of the interaction between gp-340 expressed on the cell surface and V3 loop on the HIV envelope and devices comprising these compositions.

Abstract translation: 本发明涉及用于通过HIV抑制受试者宿主细胞感染的方法组合物和装置。 具体地，本发明涉及能够通过抑制细胞表面上表达的gp-340与HIV包膜上的V3环和包含这些组合物的装置之间的相互作用来抑制宿主细胞的结合和随后感染的方法和组合物 。

公开(公告)号：US20160355545A1

公开(公告)日：2016-12-08

申请号：US14913951

申请日：2014-09-03

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  FLINDERS UNIVERSITY

Inventor： Gregory A. Weiss ,  Colin L. Raston ,  Tom Z. Yuan ,  Callum Ormonde ,  Stephan Timothy Kudlacek

IPC: C07K1/113 ,  C12N9/36 ,  C07K1/14 ,  C07K14/47 ,  C07K14/005

CPC classification number: C07K1/113 ,  C07K1/14 ,  C07K14/005 ,  C07K14/47 ,  C12N9/2462 ,  C12N2740/16111 ,  C12Y302/01017

Abstract: A method of improving protein functionality includes obtaining a protein such as protein contained within exclusion bodies contained within bacteria or yeast used for the recombinant expression of the protein. The exclusion bodies are solubilized using a chaotropic agent such as guanidine or urea. The protein is then subject to denaturation conditions and optionally purified. A liquid containing the denatured protein is loaded into a vessel that is angled relative to horizontal. The vessel is then rotated in the angled configuration at a rate within that is less than 10,000 RPM for period of time. Refolded protein is formed by the high shear conditions formed in the thin film of fluid formed in the inner surface of the rotating vessel. Refolding can be performed in a batch mode or a continuous mode. The process may be scaled up for industrial applications by using multiple vessels.

Abstract translation: 改进蛋白质功能的方法包括获得蛋白质，例如包含在用于重组表达蛋白质的细菌或酵母中的排除体内的蛋白质。 使用离液剂如胍或尿素将排除体溶解。 然后将蛋白质经历变性条件并任选地进行纯化。 含有变性蛋白质的液体被装载到相对于水平方向成角度的容器中。 然后将容器以成角度的构型以小于10,000RPM的速度旋转一段时间。 通过在旋转容器的内表面形成的流体薄膜中形成的高剪切条件形成重折叠蛋白质。 可以以分批模式或连续模式进行重折叠。 可以通过使用多个容器来扩大工业应用的进程。

公开(公告)号：US20160354462A1

公开(公告)日：2016-12-08

申请号：US15172947

申请日：2016-06-03

Applicant: Forsyth Dental Infirmary for Children

Inventor： Antonio Campos-Neto ,  Mark Cayabyab ,  Margaret Duncan

IPC: A61K39/21 ,  C07K14/005 ,  C12N9/44 ,  C07K14/35 ,  A61K45/06 ,  C12N15/74 ,  C12N7/00 ,  A61K39/04

CPC classification number: A61K39/21 ,  A61K39/04 ,  A61K45/06 ,  A61K2039/523 ,  A61K2039/542 ,  A61K2039/572 ,  C07K14/00 ,  C07K14/005 ,  C07K14/155 ,  C07K14/162 ,  C07K14/315 ,  C07K14/35 ,  C07K2319/02 ,  C07K2319/40 ,  C12N7/00 ,  C12N9/2457 ,  C12N15/74 ,  C12N15/746 ,  C12N2740/15022 ,  C12N2740/15033 ,  C12N2740/16022 ,  C12N2740/16033 ,  C12N2740/16034 ,  C12N2740/16051 ,  C12N2740/16071 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12Y302/01041

Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.

公开(公告)号：US20160272947A1

公开(公告)日：2016-09-22

申请号：US14806739

申请日：2015-07-23

Applicant: The Catholic University of America

Inventor： Venigalla B. RAO ,  Wadad ALSALMI

IPC: C12N7/00 ,  C07K14/005

CPC classification number: C07K14/005 ,  A61K9/7023 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/54 ,  A61K2039/627 ,  C07K1/22 ,  C07K1/36 ,  C07K14/162 ,  C07K2319/00 ,  C07K2319/20 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/40 ,  C07K2319/50 ,  C12N7/00 ,  C12N2740/16022 ,  C12N2740/16043 ,  C12N2740/16051 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16234

Abstract: An approach of producing recombinant trimers that mimic native HIV-1 envelope trimers is developed. A recombinant protein forming the recombinant trimers encompasses a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140. The linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix. After expressed in a cell, the recombinant protein is secreted into the culture medium and assembles into recombinant trimers therein. The recombinant trimers may be directly purified from the culture medium. Cleaved and uncleaved trimers from different clade viruses are produced.

公开(公告)号：US20160271243A1

公开(公告)日：2016-09-22

申请号：US14806751

申请日：2015-07-23

Applicant: THE CATHOLIC UNIVERSITY OF AMERICA

Inventor： Venigalla B. RAO ,  Wadad ALSALMI

IPC: A61K39/21 ,  A61K9/70

CPC classification number: C07K14/005 ,  A61K9/7023 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/54 ,  A61K2039/627 ,  C07K1/22 ,  C07K1/36 ,  C07K14/162 ,  C07K2319/00 ,  C07K2319/20 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/40 ,  C07K2319/50 ,  C12N7/00 ,  C12N2740/16022 ,  C12N2740/16043 ,  C12N2740/16051 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16234

Abstract: Provided herein are HIV vaccines that encompasses recombinant trimers that mimic native HIV-1 envelope trimers. Also provided are methods of administering to a subject in need thereof an HIV vaccine provided herein to elicit antibodies against a recombinant trimer in the subject. A recombinant trimer is formed by a recombinant protein comprising a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140, wherein the linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix during purification of the recombinant trimer.

Abstract translation: 本文提供涵盖模仿天然HIV-1包膜三聚体的重组三聚体的HIV疫苗。 还提供了向有需要的受试者施用本文提供的HIV疫苗以引发针对受试者中重组三聚体的抗体的方法。 通过重组蛋白质形成重组三聚体，所述重组蛋白质包含通过重组HIV-1 gp140的C-末端的接头与标签融合的重组HIV-1 gp140，其中所述连接体足够长，使得所述标签可通过 在纯化重组三聚体期间结合在固体基质上的结合分子。